Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.

There is considerable interest in the development of vaccination strategies that would elicit strong tumor-specific CTL responses in cancer patients. One strategy consists of using recombinant viruses encoding amino acid sequences corresponding to natural CTL-defined peptide from tumor Ags as immuno...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: Valmori, D, Lévy, F, Miconnet, I, Zajac, P, Spagnoli, G, Rimoldi, D, Liénard, D, Cerundolo, V, Cerottini, J, Romero, P
स्वरूप: Journal article
भाषा:English
प्रकाशित: 2000
_version_ 1826299664341663744
author Valmori, D
Lévy, F
Miconnet, I
Zajac, P
Spagnoli, G
Rimoldi, D
Liénard, D
Cerundolo, V
Cerottini, J
Romero, P
author_facet Valmori, D
Lévy, F
Miconnet, I
Zajac, P
Spagnoli, G
Rimoldi, D
Liénard, D
Cerundolo, V
Cerottini, J
Romero, P
author_sort Valmori, D
collection OXFORD
description There is considerable interest in the development of vaccination strategies that would elicit strong tumor-specific CTL responses in cancer patients. One strategy consists of using recombinant viruses encoding amino acid sequences corresponding to natural CTL-defined peptide from tumor Ags as immunogens. However, studies with synthetic tumor antigenic peptides have demonstrated that introduction of single amino acid substitutions may dramatically increase their immunogenicity. In this study we have used a well-defined human melanoma tumor Ag system to test the possibility of translating the immunological potency of synthetic tumor antigenic peptide analogues into recombinant vaccinia viruses carrying constructs with the appropriate nucleotide substitutions. Our results indicate that the use of a mutated minigene construct directing the expression of a modified melanoma tumor Ag leads to improved Ag recognition and, more importantly, to enhanced immunogenicity. Thus, recombinant vaccinia viruses containing mutated minigene sequences may lead to new strategies for the induction of strong tumor-specific CTL responses in cancer patients.
first_indexed 2024-03-07T05:05:23Z
format Journal article
id oxford-uuid:d9bd8ce3-459f-459f-a919-3a6c60d5dfe5
institution University of Oxford
language English
last_indexed 2024-03-07T05:05:23Z
publishDate 2000
record_format dspace
spelling oxford-uuid:d9bd8ce3-459f-459f-a919-3a6c60d5dfe52022-03-27T08:58:08ZInduction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d9bd8ce3-459f-459f-a919-3a6c60d5dfe5EnglishSymplectic Elements at Oxford2000Valmori, DLévy, FMiconnet, IZajac, PSpagnoli, GRimoldi, DLiénard, DCerundolo, VCerottini, JRomero, PThere is considerable interest in the development of vaccination strategies that would elicit strong tumor-specific CTL responses in cancer patients. One strategy consists of using recombinant viruses encoding amino acid sequences corresponding to natural CTL-defined peptide from tumor Ags as immunogens. However, studies with synthetic tumor antigenic peptides have demonstrated that introduction of single amino acid substitutions may dramatically increase their immunogenicity. In this study we have used a well-defined human melanoma tumor Ag system to test the possibility of translating the immunological potency of synthetic tumor antigenic peptide analogues into recombinant vaccinia viruses carrying constructs with the appropriate nucleotide substitutions. Our results indicate that the use of a mutated minigene construct directing the expression of a modified melanoma tumor Ag leads to improved Ag recognition and, more importantly, to enhanced immunogenicity. Thus, recombinant vaccinia viruses containing mutated minigene sequences may lead to new strategies for the induction of strong tumor-specific CTL responses in cancer patients.
spellingShingle Valmori, D
Lévy, F
Miconnet, I
Zajac, P
Spagnoli, G
Rimoldi, D
Liénard, D
Cerundolo, V
Cerottini, J
Romero, P
Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
title Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
title_full Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
title_fullStr Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
title_full_unstemmed Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
title_short Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue.
title_sort induction of potent antitumor ctl responses by recombinant vaccinia encoding a melan a peptide analogue
work_keys_str_mv AT valmorid inductionofpotentantitumorctlresponsesbyrecombinantvacciniaencodingamelanapeptideanalogue
AT levyf inductionofpotentantitumorctlresponsesbyrecombinantvacciniaencodingamelanapeptideanalogue
AT miconneti inductionofpotentantitumorctlresponsesbyrecombinantvacciniaencodingamelanapeptideanalogue
AT zajacp inductionofpotentantitumorctlresponsesbyrecombinantvacciniaencodingamelanapeptideanalogue
AT spagnolig inductionofpotentantitumorctlresponsesbyrecombinantvacciniaencodingamelanapeptideanalogue
AT rimoldid inductionofpotentantitumorctlresponsesbyrecombinantvacciniaencodingamelanapeptideanalogue
AT lienardd inductionofpotentantitumorctlresponsesbyrecombinantvacciniaencodingamelanapeptideanalogue
AT cerundolov inductionofpotentantitumorctlresponsesbyrecombinantvacciniaencodingamelanapeptideanalogue
AT cerottinij inductionofpotentantitumorctlresponsesbyrecombinantvacciniaencodingamelanapeptideanalogue
AT romerop inductionofpotentantitumorctlresponsesbyrecombinantvacciniaencodingamelanapeptideanalogue